|
|
|
|
|
16.05.25 - 13:06
|
STAAR Surgical Announces $30 Million Share Repurchase Authorization (Business Wire)
|
|
|
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock.
“Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth,” said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. “With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we are well-positioned to capitalize on opportunities ahead. Today's announcement also underscores our thoughtful and disciplined approach to capital allocation and our commitment to deliver shareholder value. We believe our shares represent an attractive investment, and t...
|
|
|
|
|
|
|
|
|
24.04.25 - 23:06
|
STAAR Surgical Announces Changes to Board of Directors (Business Wire)
|
|
|
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to serve in a short-term role as a special strategic advisor to the Company's Asia Pacific business.
“We are pleased to have Lou rejoin the STAAR Board,” said the Company's CEO and Board member, Steve Farrell. “Lou's healthcare leadership experience, financial and opera...
|
|
|
23.04.25 - 13:06
|
STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025 (Business Wire)
|
|
|
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress.
Event: STAAR Surgical 1Q 2025 Financial Results Webcast
Date: Wednesday, May 7, 2025
Time: 5:15 p.m. ET
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp
The live webcast, including an option to pre-register, can be accessed at the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/. A webcast replay will be available at the same link for at least 90 days.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
